| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/30/2011 | CA2780591A1 Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents |
| 06/30/2011 | CA2780357A1 Extracts from kibdelos porangium as antibacterial agents |
| 06/30/2011 | CA2780177A1 Abt-263 capsule |
| 06/30/2011 | CA2780161A1 Substituted benzamide derivatives |
| 06/30/2011 | CA2779532A1 Synergistic antiviral composition and use thereof |
| 06/30/2011 | CA2776342A1 Agomelatine and pharmaceutical compositions thereof |
| 06/30/2011 | CA2767068A1 Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
| 06/30/2011 | CA2687713A1 Treatment of cancer, arthritis, inflammation and other diseases by drawing on skin the big dose of vitamin e in oil and covering by film |
| 06/29/2011 | EP2339490A1 Method for determining medication efficacy |
| 06/29/2011 | EP2339351A1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 06/29/2011 | EP2339328A2 Pharmaceutical co-crystal compositions of celecoxib |
| 06/29/2011 | EP2339020A1 Diagnostic methods based on Pregnancy-associated plasma protein-A (PAAP-A) |
| 06/29/2011 | EP2339011A1 West Nile virus and Dengue 4 virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
| 06/29/2011 | EP2338996A2 Methods and compositions for reducing viral genome amounts in a target cell |
| 06/29/2011 | EP2338994A1 Regulation of oncogenes by microRNAs |
| 06/29/2011 | EP2338993A1 Regulation of oncogenes by microRNAs |
| 06/29/2011 | EP2338992A2 Antisense compounds having enhanced anti-microRNA activity |
| 06/29/2011 | EP2338991A2 Methods for use in modulating MIR-122a |
| 06/29/2011 | EP2338917A1 Sulfated derivative of gastrodia elata polysaccharide, preparation method and use thereof |
| 06/29/2011 | EP2338892A1 Prostate specific membrane antigen inhibitors |
| 06/29/2011 | EP2338891A2 Method of forming hydromorphinone compositions |
| 06/29/2011 | EP2338889A1 Diazacyclic compounds having affinity for opioid receptors |
| 06/29/2011 | EP2338888A1 Imidazopyridine derivatives as JAK inhibitors |
| 06/29/2011 | EP2338887A1 Fused heterocyclic derivative and use thereof for medical purposes |
| 06/29/2011 | EP2338886A2 Naphthalene derivatives |
| 06/29/2011 | EP2338881A1 Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications |
| 06/29/2011 | EP2338879A1 New phenylhydrazone derivatives and their use as pharmaceuticals |
| 06/29/2011 | EP2338877A1 Combretastatin Derivatives and Uses Therefor |
| 06/29/2011 | EP2338873A1 New aminotetraline derivatives |
| 06/29/2011 | EP2338524A1 Combined gene therapy for the treatment of macroscopic gliomas |
| 06/29/2011 | EP2338519A1 Agent for treating myelofibrosis |
| 06/29/2011 | EP2338518A1 Specific therapy using integrin ligands for treating cancer |
| 06/29/2011 | EP2338517A1 Method for treatment or prevention of disease associated with functional disorder of regulatory T cell |
| 06/29/2011 | EP2338508A1 A rDEN3/4delta 30(ME), rDEN2/4delta30(ME) or rDEN1/4delta30(ME) recombinant chimeric dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3' untranslated region of dengue type 4 genome, wherein said 30 nucleotide deletion corresponds to the TL2 stem-loop structure. |
| 06/29/2011 | EP2338506A2 Combinations of tumor-associated antigens for the treatment of various types of cancers |
| 06/29/2011 | EP2338499A1 5' triphosphate oligonucleotide induces anti-viral response |
| 06/29/2011 | EP2338498A1 Compositions for the inhibition of protein kinase C alpha for the treatment of diabetes mellitus |
| 06/29/2011 | EP2338497A1 Treatment and prevention of heat shock protein-associated diseases and conditions |
| 06/29/2011 | EP2338496A1 HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2alpha DERIVATIVE AS ACTIVE INGREDIENT |
| 06/29/2011 | EP2338495A1 Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease |
| 06/29/2011 | EP2338494A1 Noribogaine in the treatment of pain and drug addiction |
| 06/29/2011 | EP2338493A1 Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use |
| 06/29/2011 | EP2338492A1 Methods and compositions for the treatment of alzheimer |
| 06/29/2011 | EP2338491A2 Pharmaceutical composition comprising a beta-carboline |
| 06/29/2011 | EP2338490A2 Combinations Useful for the Treatment of Neuronal Disorders |
| 06/29/2011 | EP2338489A1 Method of providing pirfenidone therapy to a patient |
| 06/29/2011 | EP2338488A1 Drug combinations with substituted diaryl ureas for the treatment of cancer |
| 06/29/2011 | EP2338487A1 Combination therapy with PARP inhibitors |
| 06/29/2011 | EP2338486A1 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
| 06/29/2011 | EP2338485A1 Substituted 1,3-dioxoisoindolines as medicine |
| 06/29/2011 | EP2338484A1 Metabolic imprinting effects of structured lipids |
| 06/29/2011 | EP2338483A2 Method and preparation preventing and/or treating neurodegenerative or neurological disorders using choline |
| 06/29/2011 | EP2338482A2 Methods for treating neuropsychiatric disorders |
| 06/29/2011 | EP2338481A2 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
| 06/29/2011 | EP2338480A1 Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt |
| 06/29/2011 | EP2338478A1 Method for producing liposomes |
| 06/29/2011 | EP2338477A1 Suppository comprising pantoprazole |
| 06/29/2011 | EP2338476A1 Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non-esterified fatty acid |
| 06/29/2011 | EP2338475A2 Treating canker sores with patches to speed healing and relieve pain |
| 06/29/2011 | EP2338474A1 Fusion tablet containing compacted sildenafil base |
| 06/29/2011 | EP2338473A1 Pharmaceutical dosage forms of tizanidine and administration routes thereof |
| 06/29/2011 | EP2338448A2 Anti-inflammatory and antimicrobial uses for bioactive glass |
| 06/29/2011 | EP2338360A1 Alexipharmic cigarette filter material and their praparation |
| 06/29/2011 | EP2337850A2 Anti-protozoa compounds |
| 06/29/2011 | EP2337847A2 Vaccine adjuvants |
| 06/29/2011 | EP2337822A1 Long-term stable microbicide and coating for preventing biofilm formation and coating composition therefor |
| 06/29/2011 | EP2337784A1 Macrocyclic compounds as hepatitis c virus inhibitors |
| 06/29/2011 | EP2337783A1 Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors |
| 06/29/2011 | EP2337782A1 Anti-tumor activity of aechl-i, a novel triterpenoid isolated from ailanthus excelsa in vitro and in vivo |
| 06/29/2011 | EP2337781A2 Anti-viral compounds to treat hcv infection |
| 06/29/2011 | EP2337780A1 Dithiolane compounds; compositions containing them; uses for photoprotecting the skin |
| 06/29/2011 | EP2337779A2 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| 06/29/2011 | EP2337778A1 Methods of treating a botulinum toxin related condition in a subject |
| 06/29/2011 | EP2337775A1 New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis |
| 06/29/2011 | EP2337584A2 Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| 06/29/2011 | EP2337580A1 New protecting compositions for recombinantly produced factor viii |
| 06/29/2011 | EP2337578A2 Composition and methods for modulating toll-like receptor activity |
| 06/29/2011 | EP2337567A1 Veterinary preparation |
| 06/29/2011 | EP2337566A1 Combinations for the treatment of migraine |
| 06/29/2011 | EP2337565A1 Stable solid oral dosage co-formulations |
| 06/29/2011 | EP2337564A1 A method for combating adverse effects arising from antipsychotic treatment |
| 06/29/2011 | EP2337563A1 Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| 06/29/2011 | EP2337562A2 Antifungal compounds containing benzothiazinone, benzoxazinone or benzoxazolinone and process thereof |
| 06/29/2011 | EP2337561A1 Use of tocotrienol composition for the prevention of cancer |
| 06/29/2011 | EP2337560A1 Use of 5-hydroxy-2-hydroxymethyl- y -pyrone (hmp) as a leishmanicidal agent |
| 06/29/2011 | EP2337559A2 Method of treating atrial fibrillation |
| 06/29/2011 | EP2200603B1 Osmolytes for the treatment of allergic respiratory diseases |
| 06/29/2011 | EP2146986B1 Diphenyl-dihydro-imidazopyridinones |
| 06/29/2011 | EP2114937B1 Phenothiazin derivates, method for the production thereof and use thereof as pharmaceuticals |
| 06/29/2011 | EP2074122B1 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| 06/29/2011 | EP2041094B1 Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| 06/29/2011 | EP2039354B1 Compounds blocking the nmda receptor channel and pharmaceutical agent using the same |
| 06/29/2011 | EP2030978B1 Phosphine transition metal complex, method for producing the same and antitumor agent |
| 06/29/2011 | EP2026763B1 A method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (gerd) by specific polysaccharides |
| 06/29/2011 | EP2021472B1 Compounds and methods for modulating gene expression |
| 06/29/2011 | EP2004605B1 Piperidine derivatives useful as serotonin transporter inhibitors and neurokinin-1 receptor antagonists |
| 06/29/2011 | EP1928875B1 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same |
| 06/29/2011 | EP1910336B1 Monohydrochloride monohydrate salt of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 06/29/2011 | EP1907394B1 Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators |
| 06/29/2011 | EP1888585B1 Tetracyclic azapyrazinoindolines as 5-ht2 ligands |